Syndax Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Syndax Pharmaceuticals has raised $325M across 2 funding rounds on record, the most recent an undisclosed round of $250M announced in Jun 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Syndax Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Syndax Pharmaceuticals Funding Rounds
Syndax Pharmaceuticals raised $75.3M in a Post-IPO Equity announced in Dec 2021.
4.5 years later, an undisclosed round of $250M was announced in Jun 2026.
Syndax Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Syndax Pharmaceuticals Funding Compared to Other Biotechnology Startups
Syndax Pharmaceuticals' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Syndax Pharmaceuticals in Biotechnology and Waltham
Companies Similar to Syndax Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Syndax Pharmaceuticals Funding FAQs
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
How much funding has Syndax Pharmaceuticals raised?
Syndax Pharmaceuticals has raised $325M across 2 rounds on record. The most recent is an undisclosed round of $250M announced in Jun 2026.
When did Syndax Pharmaceuticals last raise funding?
Syndax Pharmaceuticals' most recent funding round on record is an undisclosed round of $250M, announced in Jun 2026.
Who founded Syndax Pharmaceuticals?
FundedIQ lists Aleksandra Rizo (Founder) at Syndax Pharmaceuticals.
Who is the CEO of Syndax Pharmaceuticals?
Briggs Morrison is listed as CEO at Syndax Pharmaceuticals.
Where is Syndax Pharmaceuticals headquartered?
Syndax Pharmaceuticals is based in Waltham, Massachusetts, United States.
How many employees does Syndax Pharmaceuticals have?
Syndax Pharmaceuticals is in the 51-100 employee band.
How does Syndax Pharmaceuticals' funding compare to other Biotechnology startups?
Syndax Pharmaceuticals' latest round of $250M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Syndax Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Syndax Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.